One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Editors and Editorial Board.
doi : 10.1161/HCV.0000000000000089
Volume 16(1) pgs. e000089-e012538 January 2023
BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
Yoon, Chang-Hwan MD ,*; Kwun, Ju-Seung MD ,*; Choi, Young Jin MD; Park, Jin Joo MD; Kang, Si-Hyuck MD; Kim, Sun-Hwa PhD; Suh, Jung-Won MD; Youn, Tae-Jin MD; Kim, Myeong-Kon MD; Cha, Kwang Soo MD; Lee, Seung-Hwan MD; Hong, Bum-Kee MD; Rha, Seung-Woon MD; Kang, Woong Chol MD; Lee, Jae-Hwan MD; Kim, Sang-Hyun MD; Chae, In-Ho MD
doi : 10.1161/CIRCINTERVENTIONS.122.012307
Comparative studies of ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES) have reported promising results and validated its excellent outcomes in terms of safety and efficacy.
Temporal Trends in In-Hospital Outcomes Following Unprotected Left-Main Percutaneous Coronary Intervention: An Analysis of 14 522 Cases From British Cardiovascular Intervention Society Database 2009 to 2017.
Kinnaird, Tim MD; Gallagher, Sean MD; Farooq, Vasim PhD; Protty, Majd PhD; Back, Liam MD; Devlin, Peadar MD; Anderson, Richard MD; Sharp, Andrew MD; Ludman, Peter MD; Copt, Samuel PhD; Mamas, Mamas A. DPhil; Curzen, Nick PhD
doi : 10.1161/CIRCINTERVENTIONS.122.012350
Percutaneous coronary intervention (PCI) is increasingly used as a treatment option for unprotected left main stem artery (unprotected left main stem percutaneous intervention) disease.
Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial.
Hansen, Kirstine Norregaard MD; Jensen, Lisette Okkels MD, PhD, DMSci; Maeng, Michael MD, PhD; Christensen, Martin Kirk MD; Noori, Manijeh MD; Kahlert, Johnny MSc, PhD; Jakobsen, Lars MD, PhD; Junker, Anders MD, PhD; Freeman, Phillip MD; Ellert-Gregersen, Julia MD, PhD; Raungaard, Bent MD, PhD; Terkelsen, Christian Juhl MD, DMSci; Veien, Karsten Tange MD; Christiansen, Evald Hoj MD, PhD
doi : 10.1161/CIRCINTERVENTIONS.122.012332
Biodegradable polymer drug-eluting stents were developed to improve safety and efficacy outcomes for patients undergoing percutaneous coronary intervention.
Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries.
Scotti, Andrea MD ,*; Baggio, Sara MD ,,*; Pagnesi, Matteo MD; Barbanti, Marco MD; Adamo, Marianna MD; Eitan, Amnon MD; Estevez-Loureiro, Rodrigo MD, PhD; Veulemans, Verena MD; Toggweiler, Stefan MD; Mylotte, Darren MD; De Marco, Federico MD; Giannini, Francesco MD; Ferlini, Marco MD; Naber, Christoph K. MD; Buono, Andrea MD; Schofer, Joachim MD, PhD; Rottbauer, Wolfgang MD; Van Mieghem, Nicolas M. MD, PhD; Khogali, Saib MD; Taramasso, Maurizio MD, PhD; Pilgrim, Thomas MD; Sinning, Jan-Malte MD; Zweiker, David MD; Montorfano, Matteo MD; Van der Heyden, Jan A.S. MD, PhD; Brugaletta, Salvatore MD, PhD; Ielasi, Alfonso MD; Hamm, Christian W. MD; Vanhaverbeke, Maarten MD; Costa, Giuliano MD; Massussi, Mauro MD; Alarcon, Robert MD; Zeus, Tobias MD; Lunardi, Mattia MD; Testa, Luca MD; Di Ienno, Luca MD; Lanzillo, Giuseppe MD; Wolf, Alexander MD; Maffeo, Diego MD; Ziviello, Francesca MD; Saccocci, Matteo MD; Windecker, Stephan MD; Sedaghat, Alexander MD; Schmidt, Albrecht MD; Brouwer, Jorn MD; Regueiro, Ander MD; Reimers, Bernhard MD; Kim, Won-Keun MD; Sondergaard, Lars MD; Colombo, Antonio MD; Mangieri, Antonio MD ,,+; Latib, Azeem MD ,+; on behalf of the NEOPRO and NEOPRO-2 Investigators
doi : 10.1161/CIRCINTERVENTIONS.122.012538
In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited.
